

1 **Signals of significantly increased vaccine breakthrough,**  
2 **decreased hospitalization rates, and less severe disease in**  
3 **patients with COVID-19 caused by the Omicron variant of**  
4 **SARS-CoV-2 in Houston, Texas**

5  
6  
7 Paul A. Christensen,<sup>\*,†,‡,§</sup> Randall J. Olsen,<sup>\*,†,‡,§</sup> S. Wesley Long,<sup>\*,†,‡,§</sup> Richard Snehal,<sup>†</sup>  
8 James J. Davis,<sup>¶,\*\*</sup> Matthew Ojeda Saavedra,<sup>†</sup> Kristina Reppond,<sup>†</sup> Madison N. Shyer,<sup>†</sup>  
9 Jessica Cambric,<sup>†</sup> Ryan Gadd,<sup>†</sup> Rashi M. Thakur,<sup>†</sup> Akanksha Batajoo,<sup>†</sup> Regan  
10 Mangham,<sup>†</sup> Sindy Pena,<sup>†</sup> Trina Trinh,<sup>†</sup> Jacob C. Kinskey,<sup>†</sup> Guy Williams,<sup>†</sup> Robert  
11 Olson,<sup>¶,\*\*</sup> Jimmy Gollihar,<sup>‡</sup> James M. Musser<sup>†,‡,§,††</sup>

12  
13 *\*Contributed equally;*

14 *† Laboratory of Human Molecular and Translational Human Infectious Diseases and*

15 *‡ Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for*

16 *Infectious Diseases, Houston Methodist Research Institute and Department of*

17 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;*

18 *§ Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New*

19 *York, New York;*

20 *¶ Consortium for Advanced Science and Engineering, University of Chicago, Chicago,*

21 *Illinois;*

22 *\*\* Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont,*  
23 *Illinois;*

24

25 *++ Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*  
26 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*  
27 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

28 [jmmusser@houstonmethodist.org](mailto:jmmusser@houstonmethodist.org)

29

30 Running head: Omicron variant in Houston, Texas

31

32 Disclosures: None.

33

34 Funding: This project was supported by the Houston Methodist Academic Institute  
35 Infectious Diseases Fund; and in part with funds from the National Institute of Allergy  
36 and Infectious Diseases, National Institutes of Health, Department of Health and Human  
37 Services, under Contract No. 75N93019C00076 (J.J.D.).

38

39 Number of text pages: 13

40 Number of figures: 2

41 Number of tables: 2

42 **Abstract**

43 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the  
44 COVID-19 pandemic. The recently described variant of concern designated Omicron  
45 (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of  
46 COVID-19 cases in many countries. Because Omicron was recognized very recently,  
47 many knowledge gaps exist about its epidemiology, clinical severity, and disease  
48 course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston  
49 Methodist healthcare system identified 2,232 symptomatic patients with infections  
50 caused by Omicron from late November 2021 through December 23, 2021. Omicron  
51 very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases.  
52 Compared to patients infected with either Alpha or Delta variants in our healthcare  
53 system, Omicron patients were significantly younger, had significantly increased  
54 vaccine breakthrough rates, and were significantly less likely to be hospitalized.  
55 Omicron patients required less intense respiratory support and had a shorter length of  
56 hospital stay, consistent with decreased disease severity. The data document the  
57 unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron  
58 variant in metropolitan Houston, and provide information about disease character.

59 [Introduction]

60

61

62 Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-

63 CoV-2 have caused two distinct COVID-19 disease surges in the United States,

64 Southeast Asia, Europe, and elsewhere ([https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)

65 [ncov/cases-updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed December 30,

66 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed

67 December 30, 2021), and remodeled the landscape of human behavior and many

68 societies. Delta replaced the Alpha variant as the cause of virtually all COVID-19 in

69 many countries ([https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)

70 [update-on-covid-19---13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)), last accessed August 18, 2021;

71 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions>

72 [anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions), last accessed

73 August 18, 2021).

74 At the start of the pandemic almost two years ago, the Houston Methodist

75 healthcare system instituted a comprehensive and integrated population genomics

76 project designed to sequence all SARS-CoV-2 samples causing COVID-19 in patients

77 cared for at our facilities, which include eight hospitals located throughout the

78 metroplex. The project was implemented when the initial Houston Methodist COVID-19

79 case was diagnosed at the end of February 2020, and has continued unabated<sup>1-6</sup>. This

80 project was facilitated by the existence of a single large diagnostic laboratory that

81 serves the entire system and is seamlessly integrated with a research institute with

82 extensive genomics expertise and capacity. A key goal was to comprehensively map

83 the population genomics, trajectory, and other features of the pandemic in metropolitan

84 Houston with a population size of approximately 7.2 million. Houston is the fourth  
85 largest city in the United States, the most ethnically diverse metropolitan area in the  
86 country, and is a major port of entry. To date, SARS-CoV-2 genomes have been  
87 sequenced from greater than 70,000 patient samples. Many features of four distinct  
88 SARS-CoV-2 waves in Houston have been described<sup>2-6</sup>.

89         The successes of rapid SARS-CoV-2 vaccine development and documented  
90 efficacy, coupled with the significant downturn of the disease wave caused by Delta in  
91 Houston and elsewhere in fall, 2021<sup>6</sup>, suggested that the pandemic was abating.  
92 However, the identification of a new VOC designated B.1.1.529 and commonly known  
93 as Omicron that has spread rapidly in South Africa and the UK has tempered this  
94 optimism<sup>7-9</sup>. Inasmuch as Omicron was recognized very recently, and much is not  
95 known about its epidemiology and clinical characteristics and course, we used our  
96 integrated infrastructure in an effort to address some pertinent knowledge gaps.  
97 Genome sequencing identified 2,232 COVID-19 patients with symptomatic disease  
98 caused by Omicron in the Houston Methodist healthcare system beginning in late  
99 November 2021 and ending December 23, 2021. In three weeks Omicron spread  
100 throughout the Houston metropolitan region and became the cause of 90% of new  
101 COVID-19 cases. Although the number of our Omicron patients is relatively small,  
102 compared to patients infected with either Alpha or Delta variants and cared for in our  
103 system, significantly fewer Omicron patients were hospitalized, and those who were  
104 hospitalized required significantly less intense respiratory support and had a shorter  
105 length of stay. We cautiously interpret our findings to be consistent with decreased  
106 disease severity among Houston Methodist Omicron patients. Many factors undoubtedly

107 have contributed, including but not limited to increased vaccination uptake, population  
108 immunity, and patient demographics such as younger age. The extent to which our  
109 findings translate to other cities and other patient populations, including children, is  
110 unknown.

111

112

## 113 **Materials and Methods**

114

### 115 **Patient Specimens**

116

117 Specimens were obtained from patients registered at Houston Methodist facilities (e.g.,  
118 hospitals and urgent care centers), and institutions in the Houston metropolitan region  
119 that use our laboratory services. The great majority of individuals had signs or  
120 symptoms consistent with COVID-19 disease. For analyses focusing on patients with  
121 COVID-19 caused by the Omicron variant, samples obtained from November 27, 2021  
122 through December 23, 2021 were used. This time frame was chosen because it  
123 represents the period during which an Omicron variant was first identified in our  
124 healthcare system and the last date of specimen collection used to generate genome  
125 sequence data for this manuscript. For analyses comparing features of patients infected  
126 with the Omicron VOC and Alpha and Delta VOCs, all patients documented to be  
127 infected with these variants in the Houston Methodist system were studied. The study  
128 included 38,062 unique patients identified in this time frame for whom we had SARS-

129 CoV-2 genome sequences. The work was approved by the Houston Methodist  
130 Research Institute Institutional Review Board (IRB1010-0199).

131

## 132 SARS-CoV-2 Molecular Diagnostic Testing

133

134 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease  
135 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital  
136 using assays granted Emergency Use Authorization (EUA) from the FDA

137 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-  
138 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple

139 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with

140 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid

141 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the Cobas SARS-

142 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay

143 using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic

144 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,

145 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were

146 performed on material obtained from nasopharyngeal swabs immersed in universal

147 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or

148 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

149 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last

150 accessed June 7, 2021).

151

## 152 SARS-CoV-2 Genome Sequencing, Genome Analysis, and Identification of 153 Variants

154

155 We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston  
156 Methodist healthcare system during the period studied. Libraries for whole SARS-CoV-2  
157 genome sequencing were prepared according to version 4  
158 (<https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312>, last  
159 accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-  
160 automated workflow used has been described previously<sup>2-6</sup>. Sequence reads were  
161 generated with an Illumina NovaSeq 6000 instrument.

162 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service  
163 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,  
164 2021, requires registration). The pipeline currently uses seqtk version 1.3-r117 for  
165 sequence trimming (<https://github.com/lh3/seqtk.git>) and minimap version 2.17 for  
166 aligning reads against the Wuhan-Hu-1 (NC\_045512.2) reference genome. Samtools  
167 version 1.11 was used for sequence and file manipulation, where maximum depth and  
168 minimum depth parameters in mpileup were set to 8,000 and 3, respectively. iVar  
169 version 1.3.1 was used for primer trimming and variant calling. Genetic lineages,  
170 VOCs, and variants of interest (VOIs) were identified based on genome sequence data  
171 and designated by Pangolin v. 3.1.17 with pangoLEARN module 2021-12-06  
172 (<https://cov-lineages.org/resources/pangolin.html>, last accessed December 12, 2021).  
173 Genome data used in this study have been deposited to GISAID [www.gisaid.org](http://www.gisaid.org).

174



## 175 S-Gene Target-Failure Assay

176

177 An S-gene target-failure (SGTF) assay (TaqPath COVID-19 Combo Kit Thermo Fisher,  
178 Inc.), was used as a surrogate marker for the Omicron VOC for some specimens  
179 collected between December 18, 2021 and January 5, 2022. From November 1, 2021  
180 onward, only Delta and Omicron were circulating in metropolitan Houston, as  
181 documented by whole-genome sequence data. Thus, samples with S-gene target failure  
182 were classified as Omicron, whereas samples yielding amplification of the S-gene were  
183 classified as a Delta variant.

184

## 185 Patient Metadata and Geospatial Analysis

186

187 Patient metadata were acquired from the electronic medical record by standard  
188 informatics methods. Figures showing geospatial distribution of spread for Omicron  
189 were generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA)  
190 using patient home address zip codes. A vaccination breakthrough case was defined as  
191 a PCR-positive sample from a patient obtained greater than 14 days after full  
192 vaccination (e.g., both doses of the Pfizer or Moderna mRNA vaccines) was completed.  
193 A booster vaccination breakthrough case was defined as a PCR-positive sample from a  
194 patient obtained greater than 14 days after receiving a third vaccine dose. For some  
195 cases, manual chart review was conducted to resolve discrepancies or clarify  
196 ambiguities.

197

198

## 199 **Results**

200

### 201 **Omicron Epidemiologic Wave**

202

203 The first Houston Methodist patient infected with an Omicron variant was identified at  
204 the end of November 2021, a time when the Delta VOC was responsible for all COVID-  
205 19 cases in metropolitan Houston<sup>6</sup>. During this period, the metropolitan area was  
206 experiencing a steady decrease in total number of new COVID-19 cases (**Figure 1**,  
207 **Figure 2**).

208 Omicron increased in frequency unusually rapidly over a three-week period in  
209 December (**Figure 1**, **Figure 2**). By December 23, the genome sequence data showed  
210 that Omicron accounted for >90% of all new COVID-19 cases in our healthcare system  
211 (**Figure 2**). This represents the fifth wave of COVID-19 cases in metropolitan Houston  
212 (**Figure 1**). The estimated case doubling time during this three-week period was  
213 approximately 1.8 days (**Figure 2**), which means that Omicron increased in relative  
214 frequency approximately three times faster than Delta had increased in our area<sup>6</sup>, an  
215 unprecedented trajectory for SARS-COV-2 infections.

216 Consistent with extensive infections caused by Omicron in southern Africa and  
217 elsewhere ([https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)  
218 [classifications.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)), last accessed December 28, 2021;  
219 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed  
220 December 28, 2021), several patients had very recent travel histories to countries with a

221 high prevalence of this VOC, suggesting acquisition of virus by some cases from abroad  
222 and importation into Houston. However, the great majority of Omicron patients had no  
223 documented travel outside the US and undoubtedly acquired the infection domestically,  
224 either in Houston or elsewhere.

225 To understand the geospatial distribution of Omicron in metropolitan Houston,  
226 patient metadata were acquired from the electronic medical record by standard  
227 informatics methods, and home address zip codes were used to visualize virus spread  
228 (**Figure 2**). The 2,232 Houston Methodist patients infected with Omicron during this  
229 period were distributed widely throughout metropolitan Houston, with 217 different zip  
230 codes represented (**Figure 2**). The widespread distribution of Omicron in the Houston  
231 metroplex in an extremely short period of time reflects the ability of this variant to spread  
232 unusually rapidly and effectively between individuals, and cause symptomatic disease.

233

## 234 Comparison of Omicron, Alpha, and Delta COVID-19 Cases

235

236 There is a considerable lack of detailed information about patients in the United States  
237 and elsewhere with COVID-19 caused by the Omicron VOC. We compared available  
238 metadata for all Houston Methodist patients infected with Omicron, Alpha, and Delta  
239 VOCs (**Table 1, Table 2**). The populations differed significantly in many characteristics,  
240 including median age, hospital admission rates, maximum respiratory support, rate of  
241 vaccine breakthrough, and median length of stay (**Table 1, Table 2**).

242 Patients infected with Omicron were significantly younger than Alpha and Delta  
243 patients (**Table 1, Table 2**). Importantly, Omicron patients were hospitalized significantly

244 less frequently than patients infected with either the Alpha or Delta variants, and had a  
245 significantly shorter median hospital length of stay (**Table 1, Table 2**).

246 We next analyzed Omicron vaccine breakthrough cases (**Table 1, Table 2**). We  
247 found 1,186 of the 2,232 total Omicron patients (53.1%) for whom we have whole  
248 genome sequence data met the CDC definition of vaccine breakthrough cases (**Table 1,**  
249 **Table 2**). There was no simple relationship between the time elapsed since  
250 administration of the second vaccination dose and the date of vaccination breakthrough.  
251 These 1,186 patients received either two doses of the Pfizer-BioNTech BNT162b2 ( $n =$   
252 865, 73%) or Moderna mRNA-1273 ( $n = 263$ , 22%), or one dose of J&J/Janssen JNJ-  
253 78436735 ( $n = 58$ , 5%) vaccine. This distribution reflects the majority use of BNT162b2  
254 vaccination doses in our health system. Compared to either Alpha or Delta patients, a  
255 significantly greater percentage of patients with breakthrough cases was caused by the  
256 Omicron VOC (53.1% compared to 3.2% and 24.3% for Alpha and Delta VOCs,  
257 respectively) (**Table 1, Table 2**). We next analyzed individuals with breakthrough cases  
258 after receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or  
259 Moderna mRNA-1273 vaccine. We found that 275 (12.3%) of the 2,232 Omicron  
260 patients met this criteria. Consistent with Omicron causing a significantly increased  
261 number of vaccine breakthrough cases, it has been reported that this variant has  
262 reduced sensitivity to antibody neutralization *in vitro*, likely in large part due to the  
263 extensive number of amino acid and other structural changes occurring in Omicron  
264 spike protein<sup>10-32</sup>.

265

266 An Omicron Sublineage With Spike Protein Polymorphism L452R

267  
268 The L452R amino acid change in spike protein of SARS-CoV-2 has arisen by  
269 convergent evolution in multiple genetic lineages throughout the course of the  
270 pandemic, most notably in the Delta VOC. L452R is located in the receptor binding  
271 domain of spike protein and has been associated with decreased antibody  
272 neutralization, escape from cell mediated immunity, and increased affinity for the ACE2  
273 receptor<sup>33, 34</sup>. L452R was present in samples of Omicron collected in South Africa as  
274 early as November 11, 2021. We found that all 43 specimens collected over the first  
275 nine days after we identified Omicron in Houston Methodist patients had the 452R  
276 amino acid replacement. Our first L452 isolate was collected on day 10. By day 16, over  
277 half the Omicron isolates collected were L452. Among the 65,109 Omicron samples  
278 deposited in GISAID as of 28 December 2021, only 727 (1.1%) have the 452R amino  
279 acid replacement and over half of these were from Houston Methodist patients. The  
280 initial high prevalence of Omicron containing 452R in spike protein in our population  
281 may represent a founder effect of the original genotype introduced into Houston.

282

### 283 Spike-Gene Target-Failure Assay

284

285 To estimate Omicron variant frequency in patient samples not yet sequenced, we  
286 performed the TaqPath COVID-19 Combo Kit assay (ThermoFisher) on 1,216 samples  
287 collected from symptomatic patients between December 18, 2021 and January 5, 2022  
288 In total, 1,093 (90%) of patient samples yielded a RT-PCR result with S-gene target-

289 failure indicative of the Omicron variant. These data are consistent with the increasing  
290 frequency of new cases of COVID-19 caused by Omicron in our population (**Figure 2**).

291

## 292 Lack of Omicron Variant BA.2 in Houston Methodist Samples

293

294 The BA.2 Omicron sublineage was first identified in November 2021 in Australia in a

295 patient who had traveled to South Africa ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/359)

296 [designation/issues/359](https://github.com/cov-lineages/pango-designation/issues/359); last accessed December 30, 2021). This sublineage does not

297 have the full set of polymorphisms characteristic of BA.1 (B.1.1.529) and also has

298 additional mutations unique to it ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/361)

299 [designation/issues/361](https://github.com/cov-lineages/pango-designation/issues/361); last accessed December 30, 2021). One important difference is

300 that sublineage BA.2 lacks the spike protein deletion at amino acid 69/70 which means

301 that it will not be detected by the SGTF assay. We inspected all full genome sequences

302 present in our large database and this sublineage was not present. This includes all

303 specimens taken from symptomatic patients or asymptomatic individuals. Thus, it is

304 likely that routine use of an SGTF assay in our population will identify all or virtually all

305 patients infected with Omicron.

306

## 307 Discussion

308

309 In this work, we describe information relevant to the surging Omicron wave in

310 metropolitan Houston. In three weeks, Omicron was first identified in our population and

311 rapidly increased to cause 90% of all new COVID-19 cases, with an estimated case  
312 doubling time of 1.8 days. The study was based on genome sequence analysis of 2,232  
313 Omicron samples taken from socioeconomically, geographically, and ethnically diverse  
314 symptomatic patients. Several key findings were made, including (i) the Omicron VOC  
315 rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an  
316 unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii)  
317 Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta  
318 VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv)  
319 significantly fewer Omicron patients required hospitalization compared to Alpha and  
320 Delta patients; (v) the median length of stay for hospitalized Omicron patients was  
321 significantly shorter than for Alpha and Delta patients, and consistent with this  
322 observation, the maximum respiratory support required for Omicron patients was  
323 significantly less than for Alpha or Delta patients. Our findings are largely consistent  
324 with many aspects of Omicron data reported from the UK, South Africa, and Canada<sup>7-9,</sup>  
325 <sup>35-37</sup> and are consistent with experimental animal infection data suggesting that Omicron  
326 causes less severe disease in mice and hamsters<sup>38-41</sup>. This study was facilitated by a  
327 comprehensive and integrated population genomics and epidemiology project<sup>2-6</sup>  
328 implemented at the end of February, 2020, when the initial COVID-19 case was  
329 diagnosed in the Houston Methodist healthcare system.

330         Because we sequence the genome of approximately 90% of SARS-CoV-2  
331 causing COVID-19 in our diverse Houston Methodist patient population, and have done  
332 so for almost two years, this means we are continuously monitoring the composition of  
333 this virus in a major US metroplex. This affords us the opportunity to rapidly assess

334 changes in SARS-CoV-2 population genomic structure in the fourth largest city in the  
335 US. However, our study has several limitations. Although we sequenced the genomes  
336 of SARS-CoV-2 causing 90% of all Houston Methodist COVID-19 cases in the study  
337 period, this sample represents only approximately 5% of cases reported in the  
338 metropolitan region. Our patient population will underrepresent some demographic  
339 groups, for example homeless individuals and pediatric patients. The samples  
340 sequenced in this study were obtained from symptomatic individuals, which means that  
341 it is possible that we failed to identify Omicron subvariants or features preferentially  
342 represented in asymptomatic individuals. It is likely that our study included some  
343 patients where Omicron was detected on hospital admission but was incidental to the  
344 primary cause of admission.

345         In the aggregate, our data add critical new information to features of Omicron  
346 genomic epidemiology and patient characteristics in the US. Further, the present study  
347 highlights the importance of analyzing SARS-CoV-2 genome data integrated with  
348 patient metadata and stresses the need to continue to do this in near-real time as the  
349 Omicron surge continues, the virus evolves, and new variants with potentially altered  
350 fitness and biomedically relevant phenotypes are generated. Analyses of this type are  
351 also important in the context of vaccine formulation and long COVID, an increasing  
352 health and economic problem globally. Finally, the strategy we have used in this and  
353 previous studies<sup>2-6</sup> are readily applicable to future infectious diseases problems that  
354 warrant special attention.

355



356 **Acknowledgments**

357

358 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support, and Dr. Sasha  
359 M. Pejerrey for editorial contributions. The research was supported by the Houston  
360 Methodist Academic Institute Infectious Diseases Fund and many generous Houston  
361 philanthropists. The funders had no role in the design and conduct of the study;  
362 collection, management, analysis, and interpretation of the data; preparation, review, or  
363 approval of the manuscript; and decision to submit the manuscript for publication.

364

365 We declare that we have no conflict of interest.

366

367 **Author Contributions**

368

369 P.A.C., R.J.O., S.W.L., and J.M.M. had full access to all study data and take  
370 responsibility for the integrity of the data and the accuracy of the data analysis; concept  
371 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or  
372 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis  
373 by P.A.C.; funding obtained by J.M.M. and J.J.D.; and overall supervision by J.M.M.  
374 P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

## 375 **References**

- 376 [1] Dhar MS, Marwal R, Vs R, Ponnusamy K, Jolly B, Bhojar RC, et al.: Genomic  
377 characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.  
378 Science 2021, 374:995-999
- 379 [2] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M,  
380 Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G,  
381 Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS,  
382 Chou CW, Javanmardi K, Finkelstein IJ, Musser JM: Molecular Architecture of Early  
383 Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major  
384 Metropolitan Area. mBio 2020, 11
- 385 [3] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J:  
386 Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in  
387 Houston, TX, revealed by 8,857 genome sequences. medRxiv 2021. [Preprint].  
388 doi:2021.2003.2016.21253753
- 389 [4] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,  
390 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd  
391 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of  
392 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,  
393 Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol  
394 2021, Oct;191(10):1754-1773.
- 395 [5] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,  
396 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,  
397 Musser JM: Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston

398 Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple  
399 Isolates of All Major Variants of Concern. *Am J Pathol* 2021, Jun;191(6):983-992  
400 [6] Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, Walley DR,  
401 Kinskey JC, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur  
402 RM, Batajoo A, Mangham R, Pena S, Trinh T, Yerramilli P, Nguyen M, Olson R, Snehal  
403 R, Gollihar J, Musser JM: Delta Variants of SARS-CoV-2 Cause Significantly Increased  
404 Vaccine Breakthrough COVID-19 Cases in Houston, Texas. *Am J Pathol* 2021, Nov  
405 11;S0002-9440(21)00480-6  
406 [7] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Lessells RJ, et al.: Rapid  
407 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *medRxiv*  
408 2021. [Preprint]. doi:2021.2012.2019.21268028  
409 [8] Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J,  
410 Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W,  
411 Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA: Rapid increase  
412 in Omicron infections in England during December 2021: REACT-1 study. *medRxiv*  
413 2021. [Preprint]. doi:2021.2012.2022.21268252  
414 [9] Sheikh AK, Steven; Woolhouse, Mark; McMenamin, Jim; Robertson, Chris. : Severity  
415 of Omicron variant of concern and vaccine effectiveness against symptomatic disease:  
416 national cohort with nested test negative design study in Scotland. The University of  
417 Edinburgh 2021  
418 [10] Meng B, Ferreira I, Abdullahi A, Kemp SA, Goonawardane N, Papa G, Fatihi S,  
419 Charles O, Collier D, Collaboration C-NBC-, Consortium TGtPJ, Choi J, Hyeon Lee J,  
420 Mlcochova P, James L, Doffinger R, Thukral L, Sato K, Gupta RK: SARS-CoV-2

- 421 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv 2021.  
422 [Preprint]. doi:2021.2012.2017.473248
- 423 [11] Zeng C, Evans JP, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T,  
424 Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu S-L:  
425 Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv 2021. [Preprint].  
426 doi:2021.2012.2016.472934
- 427 [12] Jacobsen H, Strengert M, Maass H, Ynga Durand MA, Kessel B, Harries M, Rand  
428 U, Abassi L, Kim Y, Lueddecke T, Hernandez P, Ortmann J, Heise J-K, Castell S,  
429 Gornyk D, Gloeckner S, Melhorn V, Lange B, Dulovic A, Haering J, Junker D,  
430 Schneiderhan-Marra N, Poehlmann S, Hoffmann M, Krause G, Cicin-Sain L: Diminished  
431 neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-  
432 based COVID-19 vaccinations. medRxiv 2021. [Preprint].  
433 doi:2021.2012.2021.21267898
- 434 [13] Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck  
435 B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CBEM, Knol MJ:  
436 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated  
437 and previously infected individuals, the Netherlands, 22 November to 19 December  
438 2021. medRxiv 2021. [Preprint]. doi:2021.2012.2020.21268121
- 439 [14] Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-  
440 Gardner ME, Mantus G, Nyhoff LE, Bechnack S, Alaaeddine G, Naji A, Samaha H, Lee  
441 M, Bristow L, Hussaini L, Ciric CR, Nguyen P-V, Gagne M, Roberts-Torres J, Henry AR,  
442 Godbole S, Grakoui A, Sexton M, Piantadosi A, Waggoner JJ, Douek DC, Anderson EJ,  
443 Roupheal N, Wrammert J, Suthar MS: mRNA-1273 and BNT162b2 mRNA vaccines

444 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv  
445 2021. [Preprint]. doi:2021.2012.2020.473557

446 [15] Zou j, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, Ren P, Shi P-Y:  
447 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.  
448 bioRxiv 2021. [Preprint]. doi:2021.2012.2020.473584

449 [16] Ikemura N, Hoshino A, Higuchi Y, Taminishi S, Inaba T, Matoba S: SARS-CoV-2  
450 Omicron variant escapes neutralization by vaccinated and convalescent sera and  
451 therapeutic monoclonal antibodies. medRxiv 2021. [Preprint].  
452 doi:2021.2012.2013.21267761

453 [17] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T,  
454 Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR:  
455 Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation  
456 serum. Lancet 2021. (in press). doi: 10.1016/s0140-6736(21)02844-0

457 [18] Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al.: Broadly  
458 neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature  
459 Research Briefing 2021. [Preprint]. doi:2021.2012.2012.472269

460 [19] Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair  
461 MS, Yu J, Chik KK-H, Yuen TT-T, Yoon C, To KK-W, Chen H, Yin MT, Sobieszczyk ME,  
462 Huang Y, Wang HH, Sheng Z, Yuen K-Y, Ho DD: Striking Antibody Evasion Manifested  
463 by the Omicron Variant of SARS-CoV-2. Nature Research Briefing 2021. [Preprint].  
464 doi:2021.2012.2014.472719

465 [20] Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,  
466 Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Bolland WH, Buchrieser J, Baele G,

467 Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina T, Marti J,  
468 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Lorie ES, REY F, Bruel T, Mouquet H,  
469 Andre E, Schwartz O: Considerable escape of SARS-CoV-2 variant Omicron to  
470 antibody neutralization. Nature Research Briefing 2021. [Preprint].

471 doi:2021.2012.2014.472630

472 [21] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall  
473 M, Groves N, O'Connell A-M, Simons D, Blomquist PB, Zaidi A, Nash S, Aziz NIBA,  
474 Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R,  
475 Ladhani SN, Ferguson N, Zambon M, Campbell CN, Brown K, Hopkins S, Chand M,  
476 Ramsay M, Bernal JL: Effectiveness of COVID-19 vaccines against the Omicron  
477 (B.1.1.529) variant of concern. medRxiv 2021. [Preprint]. doi:2021.2012.2014.21267615

478 [22] Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: Reduced sensitivity  
479 of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv 2021.  
480 [Preprint]. doi:2021.2012.2017.21267961

481 [23] Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, Scheepers C,  
482 Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z,  
483 Reedoy K, Cromer D, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim  
484 SSA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J, Lessells RJ, Moosa  
485 M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A: SARS-CoV-2 Omicron has  
486 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires  
487 ACE2 for infection. medRxiv 2021. [Preprint]. doi:2021.2012.2008.21267417

488 [24] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An  
489 R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X,

490 Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: B.1.1.529  
491 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. Nature  
492 Research Briefing 2021. [Preprint]. doi:2021.2012.2007.470392  
493 [25] Hansen CH, Schelde AB, Moustsen-Helms IR, Emborg H-D, Krause TG, Moelbak  
494 K, Valentiner-Branth P, Institut TIDPGaSS: Vaccine effectiveness against SARS-CoV-2  
495 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2  
496 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021. [Preprint].  
497 doi:2021.2012.2020.21267966  
498 [26] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima  
499 N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata  
500 T, Chen IP, Ott M, Doudna JA: Omicron mutations enhance infectivity and reduce  
501 antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv 2021. [Preprint].  
502 doi:2021.2012.2020.21268048  
503 [27] Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Martin DP, Reddy ST,  
504 Dillner J, Karlsson Hedestam GB, Albert J, Murrell B: Variable loss of antibody potency  
505 against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv 2021. [Preprint].  
506 doi:2021.2012.2019.473354  
507 [28] Haveri A, Solastie A, Ekström N, Österlund P, Nohynek H, Nieminen T, Palmu AA,  
508 Melin M: Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA  
509 vaccination in health care workers and elderly subjects and response to a single dose in  
510 previously infected adults. medRxiv 2021. [Preprint]. doi:2021.2012.2022.21268273  
511 [29] Arien KK, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S, Pannus  
512 P, Martens GA, Van Esbroeck M, Goossens ME, Marchant A, Bartholomeeusen K,

513 Desombere I: Three doses of the BNT162b2 vaccine confer neutralising antibody  
514 capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern. medRxiv  
515 2021. [Preprint]. doi:2021.2012.2023.21268316

516 [30] Willett BJ, Grove J, MacLean O, Wilkie C, Logan N, De Lorenzo G, et al.: The  
517 hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change,  
518 vaccine escape and a switch in cell entry mechanism. medRxiv 2022. [Preprint].  
519 doi:2022.2001.2003.21268111

520 [31] Boschi C, Colson P, Bancod A, Moal V, La Scola B: Omicron variant escapes  
521 therapeutic mAbs contrary to eight prior main VOC. bioRxiv 2022. [Preprint].  
522 doi:2022.2001.2003.474769

523 [32] Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al.: Omicron-  
524 B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv  
525 2021. [Preprint]. doi: 10.1101/2021.12.03.471045

526 [33] Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I,  
527 Uriu K, Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki  
528 Y, Minami R, Toya T, Sekiya N, Fukuhara T, Matsuura Y, Schreiber G, Ikeda T,  
529 Nakagawa S, Ueno T, Sato K: SARS-CoV-2 spike L452R variant evades cellular  
530 immunity and increases infectivity. *Cell Host Microbe* 2021, 29:1124-1136.e1111

531 [34] Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H,  
532 Wang M, Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y: The Impact of  
533 Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell* 2020,  
534 182:1284-1294 e1289



- 535 [35] Ulloa AC, Buchan SA, Daneman N, Brown KA: Early estimates of SARS-CoV-2  
536 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv  
537 2021. [Preprint]. doi:2021.2012.2024.21268382
- 538 [36] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG,  
539 Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender  
540 N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-y,  
541 Parboosing R, Wadula J, Hussey H, Davies M-A, Boulle A, von Gottberg A, Cohen C:  
542 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South  
543 Africa. medRxiv 2021. [Preprint]. doi:2021.2012.2021.21268116
- 544 [37] SARS-CoV-2 variants of concern and variants under investigation in England  
545 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron  
546 VOC-21NOV-01 (B.1.1.529) UK Health Security: UK Health Security, 2021.
- 547 [38] Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R,  
548 Prince T, Brown JC, Zhou J, Sreaton GR, Barclay WS, Owen A, Hiscox JA, Stewart  
549 JP: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B  
550 and Delta variants strains in a mouse model of severe COVID-19. bioRxiv 2021.  
551 [Preprint]. doi:2021.2012.2026.474085
- 552 [39] Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, Raymenants J,  
553 André E, Weynand B, Dallemier K, Neyts J: The omicron (B.1.1.529) SARS-CoV-2  
554 variant of concern does not readily infect Syrian hamsters. bioRxiv 2021. [Preprint].  
555 doi:2021.2012.2024.474086
- 556 [40] Diamond M, Peter H, Tadashi M, Kiyoko I-H, Shun I, Maki K, et al.: The SARS-  
557 CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and

558 hamsters Nature Portfolio 2022. 29 December 2021. [Preprint].

559 doi:<https://doi.org/10.21203/rs.3.rs-1211792/v1>


560 [41] McMahan K, Giffin V, Tostanoski L, Chung B, Siamatu M, Suthar M, Halfmann P,

561 Kawaoka Y, Piedra-Mora C, Martinot A, Kar S, Andersen H, Lewis MG, Barouch DH:


562 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv 2022.

563 [Preprint]. doi:2022.2001.2002.474743

564



566 **Figure 1** Epidemiologic curve showing five COVID-19 disease waves in Houston  
567 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-  
568 three-day moving average. Each of the five waves is shown in a different color. The first  
569 and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes.  
570 The Alpha VOC shown in the third wave, the Delta VOC shown in the fourth, and the  
571 Omicron VOC shown in the fifth wave indicate their numeric prominence in those  
572 waves. The figure should not be interpreted to mean that all cases in the third,  
573 and fifth waves were caused by Alpha, Delta, and Omicron VOCs, respectively. Rather,  
574 they are the dominant single VOCs causing disease in Houston Methodist system  
575 patients in those waves. The fifth wave shown includes data through December 23,  
576 2021. The figure was generated with Tableau version 2021.2.7 (Tableau Software, LLC,  
577 Seattle, WA), and is a modified version of one presented recently<sup>6</sup>. The curve is  
578 essentially superimposable on COVID-19 activity in all metropolitan Houston, Texas.



579  
580 **Figure 2** Increase in Omicron frequency over time and distribution in metropolitan  
581 Houston. The study time frame was November 27, 2021 through December 23, 2021.  
582 **A:** Omicron logistic growth model. The estimated case doubling time is 1.8 days. **B:**  
583 Cumulative increase in Omicron during the study period; y-axis is the cumulative  
584 number of new COVID-19 Omicron cases. At the end of the study period, Omicron  
585 caused 90% of all COVID-19 cases. **C – E:** Geospatial distribution of Omicron based on  
586 home address zip code for each patient. **C:** November 27 – December 3; **D:** November  
587 27 – December 10; **E:** November 27 – December 23. Note differences in heat map  
588 scale for each panel. Figures were generated using Tableau version 2021.2.7. (Tableau  
589 Software, LLC, Seattle, WA).

590 **Table 1. Summary of pertinent patient metadata for 5,386 unique patients infected**  
 591 **with Omicron or Alpha variants.**

	Omicron Variant	Alpha Variant	Total	Statistical Analysis
<b>No. (%) with data</b>	2232 (41.4%)	3154 (58.6%)	5386	
<b>Patient Characteristics</b>				
Median Age (Years)	39.6	50.0	45.8	$P < 0.0001$ Mann-Whitney
Female	1318 (59.1%)	1620 (51.4%)	2938 (54.5%)	$P < 0.0001$ Fisher's exact test
Male	914 (40.9%)	1534 (48.6%)	2448 (45.5%)	
<b>Ethnicity</b>				
Caucasian	707 (31.7%)	1241 (39.6%)	1948 (36.3%)	$P < 0.0001$ Chi-square
Hispanic or Latino	441 (19.8%)	946 (30.0%)	1387 (25.8%)	
Black	847 (37.9%)	729 (23.1%)	1576 (29.3%)	
Asian	90 (4.0%)	122 (3.9%)	212 (3.9%)	
Other	13 (0.6%)	32 (1.0%)	45 (0.8%)	
Unavailable	134 (6.0%)	84 (2.7%)	218 (4.0%)	
<b>BMI</b>				
Median BMI	28.8	30.5	29.8	$P < 0.0001$ Mann-Whitney
<b>Admission Data</b>				
Admitted	313 (14.0%)	1721 (54.6%)	2034 (37.8%)	$P < 0.0001$ Fisher's exact test  Odds Ratio: 0.136 (95% CI 0.118- 0.156)
Not Admitted	1919 (86.0%)	1433 (45.4%)	3352 (62.2%)	
Median LOS (Days) (Discharged patients only)	3.1	5.1	5.0	$P < 0.0001$ Mann-Whitney
<b>Max Respiratory Support</b>				
ECMO	1 (0.3%)	7 (0.4%)	8 (0.4%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	15 (4.8%)	144 (8.4%)	159 (7.8%)	

Non-Invasive Ventilation	29 (9.3%)	164 (9.5%)	193 (9.5%)	
High Flow Oxygen	22 (7.0%)	364 (21.2%)	386 (19.0%)	
Low Flow Oxygen	104 (33.2%)	722 (42.0%)	826 (40.6%)	
Room Air	142 (45.4%)	320 (18.6%)	462 (22.7%)	
<b>Mortality</b>				
Alive	2215 (99.2%)	2984 (94.6%)	5199 (96.5%)	$P < 0.0001$
Deceased	17 (0.8%)	170 (5.4%)	187 (3.5%)	Fisher's exact test  Odds Ratio: 0.135 (95% CI 0.082- 0.222)
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	19.4 n=838	22.4 n=1050	n=1888	$P < 0.0001$ Mann-Whitney
Hologic Panther	21.6 n=172	24.2 n=358	n=530	$P = .00005$ Mann-Whitney
<b>Vaccine</b>				
Not Fully Vaccinated	1046 (46.9%)	3052 (96.8%)	4098 (76.1%)	$P < 0.0001$
Fully Vaccinated	1186 (53.1%)	102 (3.2%)	1288 (23.9%)	Fisher's exact test  Odds Ratio: 33.926 (95% CI 27.388- 42.025)

592 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

593 **Table 2. Summary of pertinent patient metadata for 17,944 unique patients**  
 594 **infected with Omicron or Delta variants.**

	Omicron Variant	Delta Variant	Total	Statistical Analysis
<b>No. (%) with data</b>	2232 (12.4%)	15712 (87.6%)	17944	
<b>Patient Characteristics</b>				
Median Age (Years)	39.6	48.3	47.1	$P < 0.0001$ Mann-Whitney
Female	1318 (59.1%)	8123 (51.7%)	9441 (52.6%)	$P < 0.0001$ Fisher's exact test
Male	914 (40.9%)	7589 (48.3%)	8503 (47.4%)	
<b>Ethnicity</b>				
Caucasian	707 (31.7%)	6891 (43.9%)	7598 (42.3%)	$P < 0.0001$ Chi-square
Hispanic or Latino	441 (19.8%)	4179 (26.6%)	4620 (25.7%)	
Black	847 (37.9%)	3449 (22.0%)	4296 (23.9%)	
Asian	90 (4.0%)	528 (3.4%)	618 (3.4%)	
Other	13 (0.6%)	112 (0.7%)	125 (0.7%)	
Unavailable	134 (6.0%)	553 (3.5%)	687 (3.8%)	
<b>BMI</b>				
Median BMI	28.8	29.5	29.5	$P = 0.0001$ Mann-Whitney
<b>Admission Data</b>				
Admitted	313 (14.0%)	6763 (43.0%)	7076 (39.4%)	$P < 0.0001$ Fisher's exact test  Odds Ratio: 0.216 (95% CI 0.191- 0.244)
Not Admitted	1919 (86.0%)	8949 (57.0%)	10868 (60.6%)	
Median LOS (Days) (Discharged patients only)	3.1	5.4	5.3	$P < 0.0001$ Mann-Whitney
<b>Max Respiratory Support</b>				
ECMO	1 (0.3%)	19 (0.3%)	20 (0.3%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	15 (4.8%)	727 (10.7%)	742 (10.5%)	

Non-Invasive Ventilation	29 (9.3%)	639 (9.4%)	668 (9.4%)	
High Flow Oxygen	22 (7.0%)	1788 (26.4%)	1810 (25.6%)	
Low Flow Oxygen	104 (33.2%)	2285 (33.8%)	2389 (33.8%)	
Room Air	142 (45.4%)	1305 (19.3%)	1447 (20.4%)	
<b>Mortality</b>				
Alive	2215 (99.2%)	14879 (94.7%)	17094 (95.3%)	$P < 0.0001$
Deceased	17 (0.8%)	833 (5.3%)	850 (4.7%)	Fisher's exact test  Odds Ratio: 0.137 (95% CI 0.085-0.222)
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	19.4 n=838	21.4 n=5108	n=5946	$P < 0.0001$ Mann-Whitney
Hologic Panther	21.6 n=172	22.6 n=1294	n=1466	$P = .2222$ Mann-Whitney
<b>Vaccine</b>				
No vaccine	959 (43.0%)	11400 (72.6%)	12359 (68.9%)	$P < 0.0001$
>7 days past 1st Vaccine	87 (3.9%)	496 (3.2%)	583 (3.2%)	Chi-square
>14 days past 2nd Vaccine	911 (40.8%)	3678 (23.4%)	4589 (25.6%)	
>14 days past 3rd Vaccine	275 (12.3%)	138 (0.9%)	413 (2.3%)	

595 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay